Attached files

file filename
EX-99.1 - EX-99.1 - Flexion Therapeutics Incflxn-ex991_7.htm
8-K - 8-K - Flexion Therapeutics Incflxn-8k_20200714.htm

Slide 1

Commercial Metrics Overview July 14,2020 Exhibit 99.2

Slide 2

Commercial Metrics Overview ZILRETTA® net sales of ~$15.4 million in Q2 2020 3,858 accounts (of 5,000 targets) have purchased ZILRETTA, as of June 30, 2020; up from 3,672, as of March 31, 2020 2,983 accounts have re-ordered ZILRETTA (77% of accounts that had purchased), as of June 30, 2020; up from 2,832 accounts that had re-ordered ZILRETTA (77% of accounts that had purchased) as of March 31, 2020

Slide 3

ZILRETTA Net Sales Quarterly Since Launch Note: Flexion recognizes Zilretta sales upon receipt of product by specialty distributors and pharmacies.

Slide 4

Distribution of Accounts by ZILRETTA Purchases Cumulative Note: Flexion primarily sells ZILRETTA to specialty distributors and a specialty pharmacy; accounts (physicians, clinics and certain medical centers or hospitals) then subsequently purchase ZILRETTA directly from these specialty distributors and specialty pharmacy

Slide 5

Distribution of ZILRETTA Purchases by Accounts Cumulative Note: Flexion primarily sells ZILRETTA to specialty distributors and a specialty pharmacy; accounts (physicians, clinics and certain medical centers or hospitals) then subsequently purchase ZILRETTA directly from these specialty distributors and specialty pharmacy

Slide 6

Distribution of ZILRETTA Purchases by New and Existing Accounts Cumulative Note: Flexion primarily sells ZILRETTA to specialty distributors and a specialty pharmacy; accounts (physicians, clinics and certain medical centers or hospitals) then subsequently purchase ZILRETTA directly from these specialty distributors and specialty pharmacy

Slide 7